September 27, 2019 / 12:25 PM / 24 days ago

BRIEF-Roche says Tecentriq-Avastin cocktail shows promise in liver cancer

Sept 27 (Reuters) - Roche Holding AG:

* SAYS TECENTRIQ IN COMBINATION WITH AVASTIN SHOWS ENCOURAGING RESULTS IN PHASE IB STUDY OF PEOPLE WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA

* SAYS STUDY SHOWED A CONFIRMED OBJECTIVE RESPONSE RATE OF 36% FOR PEOPLE TREATED WITH THE TECENTRIQ AND AVASTIN COMBINATION IN UNRESECTABLE HEPATOCELLULAR CARCINOMA WHO HAVE NOT RECEIVED PRIOR SYSTEMIC THERAPY

* SAYS COMBINATION OF TECENTRIQ AND AVASTIN WAS SHOWN TO REDUCE THE RISK OF DISEASE WORSENING OR DEATH BY 45% COMPARED WITH TECENTRIQ MONOTHERAPY

* SAYS MEDIAN PFS IN THE TECENTRIQ AND AVASTIN ARM WAS 5.6 MONTHS COMPARED WITH 3.4 MONTHS IN THE TECENTRIQ MONOTHERAPY ARM

* SAYS DATA ALSO SHOWED THAT 12% OF PEOPLE HAD A COMPLETE RESPONSE TO TREATMENT AND A MEDIAN DURATION OF RESPONSE (DOR) WAS NOT YET REACHED Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below